Semaglutide and tirzepatide sit next to each other on the Las Vegas Mobile IV Therapy peptide menu at the same price, $399 for an eight to ten week supply, which makes cost a useless way to choose between them. They are not the same medication. Semaglutide acts on one receptor and tirzepatide acts on two, only one of them exists in an oral form, and the side effect profiles diverge at higher doses. Below we compare how each one works, how each is dispensed in Las Vegas, and the specific situations where a provider would point you toward one over the other.
- Semaglutide and tirzepatide at a glance
- Key things to know
- What semaglutide is
- What tirzepatide is
- Compounded is not the same as the branded product
- How they differ on cost in Las Vegas
- How they differ on clinical evidence
- How they differ on side effects and safety
- How each is dispensed in Las Vegas
- Who each one is right for
- Common questions
- Sources and references
Semaglutide and Tirzepatide at a Glance
How the two peptides compare on mechanism, route, and how each is dispensed by Las Vegas Mobile IV Therapy.
| Criterion | Semaglutide | Tirzepatide |
|---|---|---|
| Drug class | GLP-1 receptor agonist | Dual GIP and GLP-1 receptor agonist |
| Receptor targets | One | Two Dual pathway |
| Routes that exist | Subcutaneous injection or oral tablet Oral option |
Subcutaneous injection only |
| Dosing cadence | Once weekly | Once weekly |
| Price in Las Vegas | $399 | $399 |
| Supply dispensed | 8 to 10 weeks | 8 to 10 weeks |
| Form dispensed here | Patient-specific compounded vial, left with you Take home |
Patient-specific compounded vial, left with you Take home |
| FDA status of what is dispensed | Compounded, not the FDA-approved branded product | Compounded, not the FDA-approved branded product |
Key Things to Know
Four of the eight rows above are identical. The differences that actually drive a decision come down to pharmacology, route, and tolerance, not price. Here is the short version before the detail.
What Semaglutide Is
Semaglutide is a GLP-1 receptor agonist. It is a prescription medication given as a once-weekly subcutaneous injection, and it is one of two peptides in the weight and metabolic group on our semaglutide therapy in Las Vegas page. It is not delivered by IV.
How Semaglutide Works
GLP-1 is a hormone the gut releases after eating. A GLP-1 receptor agonist mimics it. According to Cleveland Clinic, semaglutide mimics GLP-1 hormones only, which is the single-pathway action that distinguishes it from tirzepatide. One of the downstream effects is slower gastric emptying, and that mechanism is also the source of the most common side effects. These statements have not been evaluated by the FDA.
How Semaglutide Is Administered
The injectable form goes into subcutaneous tissue, not into a vein. It is a weekly injection rather than a daily one, which is a meaningful practical difference for anyone who has managed a daily medication before.
Dosing Cadence
Once weekly, on the same day each week. Doses are typically started low and increased in steps, with the pace set by your prescribing provider. Nothing about that schedule is self-directed.
Route Options
Semaglutide is the only one of the two that also exists as an oral tablet. What Las Vegas Mobile IV Therapy dispenses is the injectable compounded preparation.
When Semaglutide Is Considered
Semaglutide is considered in appetite and weight management under a provider's direction. It has been in clinical use longer than tirzepatide, and per Drugs.com, its cardiovascular outcomes data is further along, while outcome studies for tirzepatide are still ongoing. Whether it suits you is a clinical decision, not a menu choice.
What Tirzepatide Is
Tirzepatide is a dual GIP and GLP-1 receptor agonist. Like semaglutide, it is a prescription medication given as a once-weekly subcutaneous injection, priced at $399 for an eight to ten week supply on the Las Vegas peptide menu.
How Tirzepatide Works
Tirzepatide acts at two receptors rather than one. Alongside GLP-1, it mimics GIP, a second gut hormone involved in the response to eating. Cleveland Clinic describes this dual action as the reason tirzepatide is classed separately from single-pathway GLP-1 agonists. It slows gastric emptying by the same general mechanism, so it shares the digestive side effect profile. These statements have not been evaluated by the FDA.
How Tirzepatide Is Administered
Subcutaneous injection, once weekly. It is not an IV treatment. Like semaglutide, it is never given during a drip visit.
Dosing Cadence
Weekly, with dose changes stepped over time under provider direction. One vial covers eight to ten weeks, so a single fill spans roughly two months of that schedule.
Route Options
Injection only. There is no oral tirzepatide, so if an oral route matters to you, that constraint settles the question before any other comparison starts.
When Tirzepatide Is Considered
Tirzepatide is considered in appetite and weight management where a provider judges dual-pathway action appropriate. It is the newer of the two, and the Obesity Medicine Association notes that research continues to accumulate on it relative to semaglutide's longer record.
Compounded Is Not the Same as the Branded Product
Most comparison articles skip this part. It changes what the rest of the comparison means. What Las Vegas Mobile IV Therapy dispenses is a patient-specific compounded preparation of semaglutide or tirzepatide. It is not the FDA-approved branded product, and we do not represent it as one.
Compounded means a pharmacy prepares the medication for an individual patient against a prescription written for that patient, rather than pulling a finished commercial product off a shelf. Compounded preparations of these molecules are not FDA-approved for the uses discussed here, so the framing throughout this page is investigational.
That distinction matters when you read clinical trial results. Trials study the branded agents, so their findings describe the molecules as studied, not a guarantee about a compounded preparation or about any individual person. For background on how this service model works, see what peptide therapy actually involves.
Semaglutide and Tirzepatide $399 each
- A patient-specific compounded vial, left with you
- An eight to ten week supply per fill
- Nurse education on dosing and drawing up
- Nurse education on self-administration
- Ordering by a provider with prescriptive authority
- Medical direction by our Medical Director
How They Differ on Clinical Evidence
The two have been compared directly. The honest summary: the evidence base is deeper for one, and more favorable for the other on a specific endpoint.
What the Head-to-Head Trial Found
SURMOUNT-5 was a 72-week open-label phase 3b trial in adults with obesity and without type 2 diabetes, comparing the two agents directly. Published in the New England Journal of Medicine, it found tirzepatide superior to semaglutide on reduction in body weight and waist circumference at week 72. That is a finding about the branded agents under trial conditions, not a projection for a compounded preparation and not a prediction about you. Individual results vary, and these statements have not been evaluated by the FDA.
What Is Still Being Studied
Superiority on one endpoint is not the whole picture. Semaglutide has the longer clinical record, and cardiovascular outcome studies for tirzepatide are still ongoing while equivalent data for semaglutide is further along. A provider weighs the maturity of the evidence alongside the trial result.
How They Differ on Side Effects and Safety
Both slow gastric emptying, so the side effect profiles overlap heavily. The divergence is one of degree, not kind.
Shared Side Effects
Nausea, vomiting, and digestive discomfort are common to both and follow directly from slowed gastric emptying. Both agents also carry FDA boxed warnings regarding the risk of thyroid C-cell tumors, per Drugs.com. Both require a prescription and a provider who knows your history.
Where the Profiles Diverge
Reported differences are dose-related rather than categorical. Tirzepatide has been associated with more stomach-related side effects at higher doses, which is one reason dosing is stepped up gradually rather than started at a target dose.
Hydration and Nutrient Support
Persistent nausea and reduced intake can leave you short on fluids, a practical problem separate from the medication itself. We cover that in a guide to hydration and B-vitamin support during GLP-1 use. It is supportive care, not a treatment for side effects, and it does not change how either medication works.
Who Each One Is Right For
Neither peptide is the default answer. The trial result does not settle it on its own. A provider matches the medication to your history, your tolerance, and the constraints you have to live with. You can see how both fit alongside our other weight-loss support services we offer.
When to Lean Toward Semaglutide
If an oral route matters to you
Semaglutide is the only one of the two that exists as an oral tablet as well as an injection. If a weekly self-injection is a real barrier rather than a mild preference, raise it early, because tirzepatide has no oral form at all.
If the longer clinical record is a priority
Semaglutide has been in use longer, and its cardiovascular outcomes data is further along than tirzepatide's. If you or your provider weigh the depth of the evidence base heavily, that favors semaglutide.
When to Lean Toward Tirzepatide
If dual-pathway action is the goal
Tirzepatide acts on GIP in addition to GLP-1, and in SURMOUNT-5 it was superior to semaglutide on body weight and waist circumference at 72 weeks. If your provider judges the dual mechanism appropriate, that is the case for it.
If injection-only is not a barrier
Choosing tirzepatide means committing to a weekly subcutaneous injection with no fallback route. For many people that is a non-issue, and once it is, the oral-form advantage on the semaglutide side stops mattering.
Sources and References
- Jastreboff AM, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). New England Journal of Medicine.
- American College of Cardiology. SURMOUNT-5: Greater Loss of Weight, Waist Circumference With Tirzepatide Than Semaglutide.
- Cleveland Clinic. Tirzepatide vs. Semaglutide: What You Should Know.
- Obesity Medicine Association. Tirzepatide vs Semaglutide: A Comprehensive Comparison for Providers.
- Drugs.com. Tirzepatide vs semaglutide: How do they compare?
